Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID‐19 infection
Yotam Bronstein, Amos Adler, Haytham Abu Katash, Ora Halutz, Yair Herishanu, Katia Levytskyi
Abstract
Immunocompromised patients have an increased risk of persistent COVID-19 disease. We report here the clinical course of two patients with hematologic malignancies hospitalized due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In both patients, viral evolution including new spike gene mutations that occurred following treatment with anti-SARS-CoV-2 antibodies preparations, including convalescent plasma and bamlanivimab. These cases demonstrate the possibility of antibody-resistant SARS-CoV-2 infections evolution in immunocompromised patients.
Topics & Concepts
AntibodyVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)MedicineCoronavirusImmunologySpike Protein2019-20 coronavirus outbreakDiseaseBiologyInfectious disease (medical specialty)Internal medicineOutbreakSARS-CoV-2 and COVID-19 ResearchImmunodeficiency and Autoimmune DisordersCOVID-19 Clinical Research Studies